Intravenous Fish Oil and Serum Fatty Acid Profiles in Pediatric Patients With Intestinal Failure-Associated Liver Disease.

@article{Ong2019IntravenousFO,
  title={Intravenous Fish Oil and Serum Fatty Acid Profiles in Pediatric Patients With Intestinal Failure-Associated Liver Disease.},
  author={M. Ong and R. Venick and S. Shew and J. Dunn and L. Reyen and T. Grogan and K. Calkins},
  journal={JPEN. Journal of parenteral and enteral nutrition},
  year={2019}
}
  • M. Ong, R. Venick, +4 authors K. Calkins
  • Published 2019
  • Medicine
  • JPEN. Journal of parenteral and enteral nutrition
    • BACKGROUND Intravenous fish oil (FO) treats pediatric intestinal failure-associated liver disease (IFALD). There are concerns that a lipid emulsion composed of ω-3 fatty acids will cause an essential fatty acid deficiency (EFAD). This study's objective was to quantify the risk for abnormal fatty acid concentrations in children treated with FO. METHODS Inclusion criteria for this prospective study were children with intestinal failure. Intravenous soybean oil (SO) was replaced with FO for no… CONTINUE READING
    View on PubMed
    europepmc.org
    6 Citations
    Highly Influential Citations
    1
    Background Citations
    2

    Paper Mentions

    Interventional Clinical Trial
    A Safety and Efficacy Study to Determine if Giving Intravenous Fish Oil Helps Children With Liver Disease
    The purpose of the study is to investigate if intravenous fish oil, commercially available as Omegaven, safely and effectively reverses parenteral nutrition associated cholestasis in… Expand
    ConditionsCholestasis
    InterventionDrug
    University of California, Los Angeles
    August 2009 - February 2019
    6 Citations
    Citation Type

    Citation Type

    Intravenous Fish Oil Monotherapy as a Source of Calories and Fatty Acids Promotes Age-Appropriate Growth in Pediatric Patients with Intestinal Failure-Associated Liver Disease.
    • 3
    Use of Fish Oil Intravenous Lipid Emulsions as Monotherapy in the Pediatric Intestinal Failure Patient: Beyond the Package Insert.
    • K. Gura, K. Calkins, M. Puder
    • Medicine
    • Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition
    • 2019
    • 2
    Intestinal failure-associated liver disease (IFALD): insights into pathogenesis and advances in management
    Intravenous Lipid Emulsions in the NICU.
    • 1
    Paediatric intestinal failure and transplantation
    Significant Published Articles for Pharmacy Nutrition Support Practice in 2019
    • Highly Influenced

    References

    SHOWING 1-10 OF 28 REFERENCES
    Intravenous Fish Oil and Pediatric Intestinal Failure–Associated Liver Disease: Changes in Plasma Phytosterols, Cytokines, and Bile Acids and Erythrocyte Fatty Acids
    • 18
    Long-Term Fish Oil Lipid Emulsion Use in Children With Intestinal Failure–Associated Liver Disease
    • 29
    Use of Fish Oil–Based Lipid Emulsions in Infants With Intestinal Failure–Associated Liver Disease
    • 11
    • PDF
    Parenteral Fish Oil as Monotherapy Prevents Essential Fatty Acid Deficiency in Parenteral Nutrition–dependent Patients
    • 87
    • PDF
    Plasma fatty acids in premature infants with hyperbilirubinemia: before-and-after nutrition support with fish oil emulsion.
    • 10
    Parenteral fish-oil-based lipid emulsion improves fatty acid profiles and lipids in parenteral nutrition-dependent children.
    • 47
    • PDF
    Essential fatty acid status in children with cholestasis, in relation to serum bilirubin concentration.
    • 37
    Platelet Arachidonic Acid Deficiency May Contribute to Abnormal Platelet Function During Parenteral Fish Oil Monotherapy in a Piglet Model.
    • 18
    Long-Term Outcomes in Children With Intestinal Failure-Associated Liver Disease Treated With 6 Months of Intravenous Fish Oil Followed by Resumption of Intravenous Soybean Oil.
    • 16
    Intravenous fat emulsions reduction for patients with parenteral nutrition-associated liver disease.
    • 114